Literature DB >> 26123954

Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan.

David L Saunders1, Eric Garges2, Jessica E Manning2, Kent Bennett2, Sarah Schaffer2, Andrew J Kosmowski2, Alan J Magill2.   

Abstract

Long-term antimalarial chemoprophylaxis is currently used by deployed U.S. military personnel. Previous small, short-term efficacy studies have shown variable rates of side effects among patients taking various forms of chemoprophylaxis, though reliable safety and tolerability data on long-term use are limited. We conducted a survey of troops returning to Fort Drum, NY following a 12-month deployment to Operation Enduring Freedom, Afghanistan from 2006 to 2007. Of the 2,351 respondents, 95% reported taking at least one form of prophylaxis during their deployment, and 90% were deployed for > 10 months. Compliance with daily doxycycline was poor (60%) compared with 80% with weekly mefloquine (MQ). Adverse events (AEs) were reported by approximately 30% with both MQ and doxycycline, with 10% discontinuing doxycycline compared with 4% of MQ users. Only 6% and 31% of soldiers reported use of bed nets and skin repellents, respectively. Compliance with long-term malaria prophylaxis was poor, and there were substantial tolerability issues based on these anonymous survey results, though fewer with MQ than doxycycline. Given few long-term antimalarial chemoprophylaxis options, there is an unmet medical need for new antimalarials safe for long-term use. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26123954      PMCID: PMC4559701          DOI: 10.4269/ajtmh.15-0245

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

1.  Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers.

Authors:  Christine Korhonen; Katia Peterson; Catherine Bruder; Paul Jung
Journal:  Am J Prev Med       Date:  2007-09       Impact factor: 5.043

2.  Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial.

Authors:  C Ohrt; T L Richie; H Widjaja; G D Shanks; J Fitriadi; D J Fryauff; J Handschin; D Tang; B Sandjaja; E Tjitra; L Hadiarso; G Watt; F S Wignall
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis.

Authors:  Joe P Bryan
Journal:  Am J Trop Med Hyg       Date:  2006-09       Impact factor: 2.345

4.  [Esophageal involvement after tetracycline ingestion].

Authors:  V Champel; A P Jonville-Béra; F Béra; E Autret
Journal:  Therapie       Date:  1997 Nov-Dec       Impact factor: 2.070

Review 5.  Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications.

Authors:  Leon H Kircik
Journal:  J Drugs Dermatol       Date:  2010-11       Impact factor: 2.114

6.  An efficacy trial of doxycycline chemoprophylaxis against leptospirosis.

Authors:  E T Takafuji; J W Kirkpatrick; R N Miller; J J Karwacki; P W Kelley; M R Gray; K M McNeill; H L Timboe; R E Kane; J L Sanchez
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

7.  Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis.

Authors:  Frédéric Pagès; Jean-Paul Boutin; Jean-Baptiste Meynard; Annick Keundjian; Serge Ryfer; Luciano Giurato; Dominique Baudon
Journal:  Trop Med Int Health       Date:  2002-11       Impact factor: 2.622

8.  Spatial epidemiology of Plasmodium vivax, Afghanistan.

Authors:  Simon Brooker; Toby Leslie; Kate Kolaczinski; Engineer Mohsen; Najeebullah Mehboob; Sarah Saleheen; Juma Khudonazarov; Tim Freeman; Archie Clements; Mark Rowland; Jan Kolaczinski
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

9.  Malaria reemergence in northern Afghanistan.

Authors:  Michael K Faulde; Ralf Hoffmann; Khair M Fazilat; Achim Hoerauf
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

10.  Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan.

Authors:  Remington L Nevin; Paul P Pietrusiak; Jennifer B Caci
Journal:  Malar J       Date:  2008-02-11       Impact factor: 2.979

View more
  14 in total

1.  Delayed Onset of Plasmodium falciparum Malaria after Doxycycline Prophylaxis in a Soldier Returning from the Central African Republic.

Authors:  Emilie Javelle; Marylin Madamet; Tiphaine Gaillard; Guillaume Velut; Corinne Surcouf; Rémy Michel; Eric Garnotel; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Approval of Tafenoquine for Malaria Chemoprophylaxis.

Authors:  Jonathan D Berman
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

3.  Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members.

Authors:  Angelia A Eick-Cost; Zheng Hu; Patricia Rohrbeck; Leslie L Clark
Journal:  Am J Trop Med Hyg       Date:  2016-11-14       Impact factor: 2.345

4.  Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the Wars in Iraq and Afghanistan.

Authors:  Aaron I Schneiderman; Yasmin S Cypel; Erin K Dursa; Robert M Bossarte
Journal:  Am J Trop Med Hyg       Date:  2018-06-21       Impact factor: 2.345

Review 5.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

6.  Deployment and Travel Medicine Knowledge, Attitudes, Practices, and Outcomes Study (KAPOS): Malaria Chemoprophylaxis Prescription Patterns in the Military Health System.

Authors:  Patrick W Hickey; Indrani Mitra; Jamie Fraser; David Brett-Major; Mark S Riddle; David R Tribble
Journal:  Am J Trop Med Hyg       Date:  2020-04-23       Impact factor: 2.345

7.  The risk of imported malaria in security forces personnel returning from overseas missions in the context of prevention of re-introduction of malaria to Sri Lanka.

Authors:  Sumadhya Deepika Fernando; Priyani Dharmawardana; Saveen Semege; Geetha Epasinghe; Niroshana Senanayake; Chaturaka Rodrigo; Risintha Premaratne
Journal:  Malar J       Date:  2016-03-08       Impact factor: 2.979

8.  Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study.

Authors:  Michele D Spring; Sathit Pichyangkul; Chanthap Lon; Panita Gosi; Kosol Yongvanichit; Utaiwan Srichairatanakul; Amporn Limsalakpeth; Chaiyaporn Chaisatit; Soklyda Chann; Sabaithip Sriwichai; Montida Auayapon; Suwanna Chaorattanakawee; Sheetij Dutta; Satharath Prom; Char Meng Chour; Douglas S Walsh; Evelina Angov; David L Saunders
Journal:  Malar J       Date:  2016-01-08       Impact factor: 2.979

Review 9.  Safety of antimalarial medications for use while scuba diving in malaria Endemic Regions.

Authors:  Kyle Petersen; David P Regis
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-10-11

10.  An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model.

Authors:  Jeffrey Livezey; Patrick Twomey; Meshell Morrison; Susan Cicatelli; Elizabeth H Duncan; Melinda Hamer; Christine Lee; Jack Hutter; Kristin Mills; Jesse DeLuca; Lucas Poon; Daniel Selig; Chau Vuong; Jason Sousa; Thomas Oliver; Jason Bennett; James E Moon; April Sikaffy; Martha Sedegah; Donna Tosh; Mara Kreishman-Deitrick; Paige Waterman
Journal:  Malar J       Date:  2020-09-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.